PWM
VTGN icon

Prosperity Wealth Management’s VistaGen Therapeutics VTGN Stock Holding History

Prosperity Wealth Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27,600
Closed -$69K – 284
2025
Q1 		$69K Sell
27,600
-1,650
-6% -$4.67K 0.03% 212
2024
Q4 		$86.3K Buy
+29,250
New +$82.3K 0.04% 201

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosperity Wealth Management's VTGN Position: Q2 2025 in Review

Prosperity Wealth Management sold out of VistaGen Therapeutics (VTGN) in Q2 2025, closing a stake of 27,600 shares — an estimated $69K sold.

Prosperity Wealth Management first reported a position in VTGN in Q4 2024 and held it in 2 quarters. The position peaked at $86.3K in Q4 2024. 51 funds tracked by Wall St. Rank hold VTGN as of Q2 2025.

  • Prosperity Wealth Management reported no remaining VistaGen Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Prosperity Wealth Management sold 27,600 VistaGen Therapeutics shares in Q2 2025, an estimated $69K.
  • Prosperity Wealth Management first reported a position in VistaGen Therapeutics in Q4 2024 and held it in 2 quarters.
  • Prosperity Wealth Management's VistaGen Therapeutics position peaked at $86.3K in Q4 2024.
  • 51 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2025.

Based on Prosperity Wealth Management's 13F filing for Q2 2025, filed 5 Aug 2025.